Bryn Mawr Capital Management LLC Acquires 47,964 Shares of Royalty Pharma plc (NASDAQ:RPRX)

Bryn Mawr Capital Management LLC lifted its position in Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 564.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 56,464 shares of the biopharmaceutical company's stock after purchasing an additional 47,964 shares during the quarter. Bryn Mawr Capital Management LLC's holdings in Royalty Pharma were worth $1,440,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Swedbank AB increased its holdings in Royalty Pharma by 2.0% in the 3rd quarter. Swedbank AB now owns 11,027,370 shares of the biopharmaceutical company's stock valued at $311,964,000 after buying an additional 213,900 shares during the period. Blue Trust Inc. increased its stake in Royalty Pharma by 362.7% in the third quarter. Blue Trust Inc. now owns 1,203 shares of the biopharmaceutical company's stock valued at $32,000 after acquiring an additional 943 shares during the period. Raymond James & Associates raised its position in Royalty Pharma by 9.7% in the third quarter. Raymond James & Associates now owns 805,080 shares of the biopharmaceutical company's stock worth $22,776,000 after purchasing an additional 71,402 shares in the last quarter. Lecap Asset Management Ltd. bought a new position in Royalty Pharma during the third quarter worth about $1,023,000. Finally, Keene & Associates Inc. bought a new position in Royalty Pharma during the third quarter worth about $539,000. 54.35% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on RPRX. TD Cowen raised Royalty Pharma to a "strong-buy" rating in a report on Tuesday, December 24th. StockNews.com upgraded Royalty Pharma from a "hold" rating to a "buy" rating in a research report on Tuesday, November 5th. Finally, Citigroup cut their price objective on Royalty Pharma from $60.00 to $40.00 and set a "buy" rating for the company in a report on Friday, October 25th. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Royalty Pharma presently has a consensus rating of "Buy" and an average price target of $41.60.

Royalty Pharma Price Performance

RPRX stock traded up $0.09 during midday trading on Friday, reaching $33.42. 4,620,587 shares of the company's stock traded hands, compared to its average volume of 4,453,247. The company has a 50-day simple moving average of $29.01 and a two-hundred day simple moving average of $27.89. The company has a quick ratio of 1.44, a current ratio of 1.44 and a debt-to-equity ratio of 0.64. Royalty Pharma plc has a 1-year low of $24.05 and a 1-year high of $33.69. The company has a market cap of $19.69 billion, a price-to-earnings ratio of 23.05, a PEG ratio of 2.26 and a beta of 0.49.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last announced its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 EPS for the quarter, topping the consensus estimate of $0.99 by $0.16. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. On average, analysts anticipate that Royalty Pharma plc will post 4.49 earnings per share for the current year.

Royalty Pharma Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 21st will be given a $0.22 dividend. This represents a $0.88 annualized dividend and a yield of 2.63%. The ex-dividend date is Friday, February 21st. This is a boost from Royalty Pharma's previous quarterly dividend of $0.21. Royalty Pharma's dividend payout ratio (DPR) is presently 57.93%.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.